Research Project
Grant-in-Aid for Early-Career Scientists
There are several chemotherapy regimen to treat soft tissue sarcoma. Trabectedin is one of the drugs for advanced soft tissue sarcoma. It is important to reveal the biomarker to predict the efficacy of trabectedin. The purpose of this research was to elucidate the biomarker of trabectedin to predict the efficacy through genomic analysis of tumor specimens and mechanism of resistance to trabectedin. We identified several possible genomic biomarker, and will perform more analysis in the future.
悪性軟部腫瘍に対する化学療法薬の複数選択肢がある中で、そのバイオマーカーを同定することが求められている。本研究は進行例悪性軟部腫瘍に対して保険適応となっているトラベクテジンの奏効性を予測する指標を腫瘍の遺伝子解析を行うことで、同定することを目的とした。本研究の結果、効果予測の候補となる遺伝子が挙げられたためさらなる解析を行う予定である。
All 2019 2018
All Journal Article (4 results) (of which Int'l Joint Research: 1 results, Peer Reviewed: 2 results, Open Access: 1 results) Presentation (4 results) (of which Int'l Joint Research: 1 results, Invited: 1 results)
Cancer
Volume: 126 Issue: 6 Pages: 1253-1263
10.1002/cncr.32661
Case Reports in Orthopedics
Volume: 2019 Pages: 1-7
10.1155/2019/3015675
International Journal of Cancer
Volume: 145 Issue: 12 Pages: 3276-3284
10.1002/ijc.32421
International Journal of Clinical Oncology
Volume: 24 Issue: 4 Pages: 437-444
10.1007/s10147-018-1370-8